Similarly, AlCVCT26@D‐Gel did not promote tumor infiltration of CD8+ T cells, likely due to the known fact that allogeneic cell‐derived vaccines lack patient‐specific neoantigen reactivity, which is thought to be important for generating anti‐tumor immunity. This evidence concerns the gene CD8A and neoplasm.